Patients with RP demonstrated preferences in VF-ADL and life expectancy associated with deterioration in visual function and potential treatment benefits that differ from those of the public. Considering patient preferences is critical to understand disease burden and estimate the value of therapeutic interventions.
Marsh et al. (Mon,) studied this question.